Elevance Health heads into mid-August with an unusual dynamic: insiders buying aggressively into a stock that just took its biggest single-day earnings hit in recent memory, while short sellers use the recovery to trim their positions.
The insider story is the week's most compelling angle. On July 17 — two days after the stock collapsed 12.6% on Q2 earnings — CEO Gail Boudreaux stepped in with two separate purchases totalling 2,725 shares at prices between $366 and $369, spending just over $1 million of her own capital. The independent chairman, Ramiro Peru, also bought 1,000 shares on the same day. That kind of executive buying, at the bottom of an earnings-driven flush, carries more signal than routine open-market activity. The net insider position over the past 90 days is positive — roughly 5,800 shares and $2.2 million in net value — tilting decisively to the buy side once the CEO purchases are factored in.
Short sellers, meanwhile, are heading for the exit. Short interest has fallen almost 12% over the past month to around 2.5% of free float — a level that signals modest institutional skepticism rather than any structural bear thesis. The weekly decline alone is 3.4%. The borrow market underscores just how little conviction there is on the short side: cost to borrow has dropped 39% over the past week to a near-negligible 0.24%, and availability is effectively uncapped, with over 162 million shares available to lend against fewer than 6 million shorted. There is no squeeze pressure here, and no urgency in the lending market in either direction.
Options positioning is similarly quiet. The put/call ratio is running at 0.77, only fractionally above its 20-day average of 0.76 — a z-score of 0.44, barely a rounding error from neutral. With the 52-week range spanning 0.60 to 0.91, the current reading is comfortably in the middle of the distribution. Options traders are neither hedging aggressively nor expressing strong bullish conviction. The market has processed the earnings shock and moved on.
The Street's reaction to the Q2 miss was a split verdict. Most analysts maintained their ratings but recalibrated targets in opposing directions. Wells Fargo trimmed its Overweight target to $473, and Barclays cut to $457, both signalling continued confidence in the direction of travel but acknowledging the near-term margin pressure. Leerink and Baird actually raised their targets — Leerink to $395 from $364, Baird to $393 from $331 — while Guggenheim moved its Buy target up to $455. The consensus mean sits near $449, roughly 15% above the current price of $390. On valuation, the stock trades at about 13.6x trailing earnings and 10.3x EV/EBITDA — the P/E multiple has compressed by more than a point over the past month, reflecting the post-earnings reset. The bull case centres on Medicare Advantage margin recovery and disciplined claims management; the bear case points to Medicaid headwinds and the lowered EPS guidance near $25.54 for 2026.
The earnings history drives home why the July reaction mattered. The most recent print produced a 12.6% one-day decline followed by a further 8.8% loss over the following week — a double leg down that left the stock trading well below where analysts had been modelling fair value. The recovery since then has been partial: up 3.3% on the week but still down 6.2% over the past month. Close managed-care peers CNC and MOH each gained around 1-2% on the week, while UNH slipped 1.3% and HUM gained 2.9% — suggesting ELV's partial recovery tracks the sector rather than outperforming it.
The next earnings print is scheduled for October 14. Between now and then, the key question is whether the Q3 Medicaid margin data supports the company's own guidance for a Medicaid breakeven, or whether the pressure that caught the market off guard in Q2 persists into the second half.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
